Role and evolution of therapeutic options (original) (raw)
Access this article
Subscribe and save
- Starting from 10 chapters or articles per month
- Access and download chapters and articles from more than 300k books and 2,500 journals
- Cancel anytime View plans
Buy Now
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Instant access to the full article PDF.
References
- Lees B, Molleson T, Arnett TR, Stevenson JC. Differences in proximal femur bone density over two centuries. Lancet 1993;341:673–5.
Google Scholar - Kanis JA. The incidence of hip fracture in Europe. Osteoporosis Int 1993;3 (Suppl 1):S10–5.
Google Scholar - Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878–83.
Google Scholar - Reid IA, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328:460–4.
Google Scholar - Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124–8.
Google Scholar - Orimo H, Shiraki M, Hayashi Y, et al. Effects of lα-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370–6.
Google Scholar - Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357–62.
Google Scholar - Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fracture in elderly women. BMJ 1994;308:1081–2.
Google Scholar - Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941;116:2465–74.
Google Scholar - Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980;2:1151–4.
Google Scholar - Lindsay R, Hart DM, Purdie P, et al. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978;54:193–5.
Google Scholar - Christiansen C, Riis BJ. 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990;71:836–41.
Google Scholar - Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141–6.
Google Scholar - Steinberg KK, Smith SJ, Thacker SB, Stoup DF. Breast cancer risk and duration of estrogen use: the role of the study design in meta-analysis. Epidemiology 1994;5:415–21.
Google Scholar - Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;322:1589–93.
Google Scholar - Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994;4:314–9.
Google Scholar - Hassager C, Podenphant J, Riis BJ, et al. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism 1989;38:238–42.
Google Scholar - Overgard K, Hansen MA, Jensen SB, Christiansen C. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ 1992;305:556–61.
Google Scholar - Mamelle M, Meunier PJ, Dusan R, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361–5.
Google Scholar - Buckle RM. Three-year study of sodium fluoride treatment on vertebral fracture incidence in osteoporosis. J Bone Miner Res 1989;4(Suppl 1): S186.
- Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–9.
Google Scholar - Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med 1995;123:401–8.
Google Scholar - Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.
Google Scholar - Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557–67.
Google Scholar - Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;2:1469–71.
Google Scholar - Libermann UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437–43.
Google Scholar - Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980;280:1340–4.
Google Scholar - Slovik DM, Neer RM, Potts JT Jr. Short-term effects of synthetic human parathyroid hormone (1-34) administration on bone mineral metabolism in osteoporotic patients. J Clin Invest 1981;68:1261–71.
Google Scholar - Brandi ML. New treatment strategies: ipriflavone, strontium, vitamin D metabolites and analogs. Am J Med 1993;95(Suppl 5A):69S-74S.
Google Scholar